Smooth Drug Development November 2024 News Release

Monthly News – November 2024

We are pleased to share the latest updates from Smooth Drug Development for November 2024. 

New Projects

This month, we secured and launched several exciting initiatives:

• Phase III Trial in Gynecology: Signed a full-service contract and initiated the project.
• Medical Writing Services: Contracts signed for bioequivalence studies with Tiloron and Mirtazapine.
• Phase II Study with Cetirizine: Finalizing the agreement for this important project.

Clinical and Scientific Departments News:

Our clinical teams continue to deliver outstanding progress:

• Completed the clinical phases of two bioequivalence studies with Bempedoic acid.
• Enrolled 50 subjects in the oncology BE study.
• Enrolled 47 patients in the Pembrolizumab trial.
• All patients in the Eculizumab trial reached six months of treatment.

These accomplishments underscore our unwavering commitment to advancing research and delivering high-quality outcomes.

Business Development News:

Our Business Development team ended the year with active participation in key industry events:

• Attended Bio-Europe in Stockholm, Sweden.
• Participated in RegLek in Europe.